Fracture Care
Risk Factors for Fracture Nonunion
Patients with high risk factors that factor into fracture becoming non-union.
The information provided herein includes discussion of uses of autologous platelet-rich plasma (“PRP”) that have not been approved by the U.S. Food and Drug Administration (FDA). This information is being provided at your request and is intended solely for scientific and medical educational purposes. Bioventus does not recommend or promote the unapproved use of any product. Treatment decisions should be based on the clinical judgment of a qualified healthcare professional.
The XCELL PRP® system is cleared by FDA for the safe and rapid preparation of autologous platelet-rich plasma from a small sample of peripheral blood at the patient’s point of care. The PRP is mixed with autograft and/or allograft bone prior to application to a bony defect for improving handling characteristics. It is not cleared or approved by the FDA for treatment of any specific medical condition or therapeutic indication.